We develop novel products based on our proprietary technologies for precision metering of gas flow. Our first commercial product, the CoSense® ETCO Monitor, measures end-tidal carbon dioxide (ETCO) in exhaled breath. The CoSense Monitor
aids in the detection hemolysis, which is the breakdown of red blood cells. When present in babies with jaundice, hemolysis is a dangerous condition that
can lead to long-term developmental disabilities. The CoSense Monitor also aids in the detection of smoke inhalation and carbon
monoxide poisoning. We have recently commenced commercial sales of the CoSense devices and sampling sets. The CoSense Monitor is the first 510(k) cleared and CE mark approved device based on our Sensalyze™ Technology Platform. Our
Sensalyze Technology Platform combines hardware, sensors, and software to provide a novel platform for non-invasive breath-based detection of various
analytes. Our current development pipeline includes proposed devices for asthma in children, assessment of blood carbon dioxide, or CO2,
concentration in neonates, and malabsorption in infants.
Our therapeutic technology is based upon the observation that non-inhaled CO2 delivered at a low-flow rate into the nasal cavity alleviates the
symptoms related to allergies as well as trigeminally mediated pain conditions such as trigeminal neuralgia, cluster headache and migraine. We are
currently developing the technology for these indications.